Sierra Oncology Inc (SRRA) Fundamental Analysis & Valuation

NASDAQ:SRRA • US82640U4040

Current stock price

54.99
+0.02 (+0.04%)
At close:
54.99
0 (0%)
After Hours:

This SRRA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. SRRA Profitability Analysis

1.1 Basic Checks

  • SRRA had negative earnings in the past year.
SRRA Yearly Net Income VS EBIT VS OCF VS FCFSRRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 -20M -40M -60M -80M

1.2 Ratios

Industry RankSector Rank
ROA -36.67%
ROE N/A
ROIC -30.38%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SRRA Yearly ROA, ROE, ROICSRRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 -20 -40 -60 -80 -100

1.3 Margins

  • SRRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SRRA Yearly Profit, Operating, Gross MarginsSRRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 -5K -10K -15K -20K -25K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. SRRA Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SRRA is destroying value.
  • The number of shares outstanding for SRRA has been increased compared to 1 year ago.
  • There is no outstanding debt for SRRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SRRA Yearly Shares OutstandingSRRA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 5M 10M 15M
SRRA Yearly Total Debt VS Total AssetsSRRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 50M 100M 150M

2.2 Solvency

  • An Altman-Z score of 38.91 indicates that SRRA is not in any danger for bankruptcy at the moment.
  • A Debt/Equity ratio of 0.02 indicates that SRRA is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 38.91
ROIC/WACC-3.13
WACC9.71%
SRRA Yearly LT Debt VS Equity VS FCFSRRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 21.27 indicates that SRRA has no problem at all paying its short term obligations.
  • SRRA has a Quick Ratio of 21.27. This indicates that SRRA is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 21.27
Quick Ratio 21.27
SRRA Yearly Current Assets VS Current LiabilitesSRRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. SRRA Growth Analysis

3.1 Past

  • The earnings per share for SRRA have decreased by -7.29% in the last year.
  • The Revenue for SRRA has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-7.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • SRRA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.88% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y31.62%
EPS Next 2Y20.36%
EPS Next 3Y26.06%
EPS Next 5Y14.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SRRA Yearly Revenue VS EstimatesSRRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2023 2024 2025 2026 200M 400M 600M 800M 1B
SRRA Yearly EPS VS EstimatesSRRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -100 -200 -300 -400

More info and screens

Find the best growth stocksShow best growing peers

1

4. SRRA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SRRA. In the last year negative earnings were reported.
  • Also next year SRRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SRRA Price Earnings VS Forward Price EarningsSRRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -10.5
SRRA Per share dataSRRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

  • SRRA's earnings are expected to grow with 26.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.36%
EPS Next 3Y26.06%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SRRA Dividend Analysis

5.1 Amount

  • No dividends for SRRA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

SRRA Fundamentals: All Metrics, Ratios and Statistics

Sierra Oncology Inc

NASDAQ:SRRA (6/30/2022, 8:00:01 PM)

After market: 54.99 0 (0%)

54.99

+0.02 (+0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06
Earnings (Next)08-04
Inst Owners1.64%
Inst Owner Change0%
Ins Owners25.13%
Ins Owner Change0%
Market Cap1.34B
Revenue(TTM)N/A
Net Income(TTM)-102.68M
Analysts76
Price Target56.1 (2.02%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.13
P/tB N/A
EV/EBITDA -10.5
EPS(TTM)-6.77
EYN/A
EPS(NY)-3.94
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS10.71
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -36.67%
ROE N/A
ROCE N/A
ROIC -30.38%
ROICexc N/A
ROICexgc -30.38%
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 21.27
Quick Ratio 21.27
Altman-Z 38.91
F-Score3
WACC9.71%
ROIC/WACC-3.13
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
EPS Next Y31.62%
EPS Next 2Y20.36%
EPS Next 3Y26.06%
EPS Next 5Y14.88%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Sierra Oncology Inc / SRRA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for Sierra Oncology Inc?

ChartMill assigns a fundamental rating of 3 / 10 to SRRA.


What is the valuation status for SRRA stock?

ChartMill assigns a valuation rating of 1 / 10 to Sierra Oncology Inc (SRRA). This can be considered as Overvalued.


How profitable is Sierra Oncology Inc (SRRA) stock?

Sierra Oncology Inc (SRRA) has a profitability rating of 1 / 10.


What is the financial health of Sierra Oncology Inc (SRRA) stock?

The financial health rating of Sierra Oncology Inc (SRRA) is 8 / 10.


Can you provide the expected EPS growth for SRRA stock?

The Earnings per Share (EPS) of Sierra Oncology Inc (SRRA) is expected to grow by 31.62% in the next year.